Marketing Vitals

The episode surfaces some genuinely useful compliance alerts for pharmacy operators - GLP-1 compounding liability, TCPA exposure, AI ownership liability - but the conversation is short, padded with affirmations, and rarely goes more than one level deep on any topic. The nuggets are real but sparse.

“TCPA is probably the most litigated lawsuits in the world right now”

“the FDA had like 77,000 employees out of that if I remember correctly. A thousand are in um, advertising and promotion, just cdr”

A few moderately fresh angles - analogising pre-printed GLP-1 compound sheets to DEA-era prescription pads, flagging peptides as the next compliance wave - but most of the advice is standard 'comply or face consequences' warnings that any healthcare compliance professional would already know.

“we're doing the exact same thing in this um, in the GLP one world...you're adding something to, quote, unquote, customize it, but it's a pre printed sheet”

“I think the next step is going to be peptides and I think that's going to raise all kinds of new havoc that we simply don't know how to deal with”

Kulkarni is a genuine practitioner - licensed pharmacist, regulatory attorney, law professor at Drexel teaching pharmaceutical marketing, and active conference speaker - giving him direct, multi-disciplinary credibility on the topic. He is not a high-profile operator at scale, but he is legitimately qualified.

“I teach, uh, at Drexel Law. I teach pharmaceutical marketing”

“I was. I just attended a conference, uh, last week in New York where I was presenting on it”

There are a handful of concrete specifics - FDA headcount, the Hims DOJ referral, 503A/503B distinctions, a $50/month ADA widget cost - but the guest frequently hedges or self-corrects ('I can't remember,' 'going back several years'), and many claims are asserted without data or named cases.

“the FDA had like 77,000 employees out of that if I remember correctly. A thousand are in um, advertising and promotion, just cdr”

“I can't remember whether it was Roe or hims in my memory. I'm sure we could double check that”

The host asks reasonable scene-setting questions and occasionally adds relevant client-side context, but she largely lets the guest roam without probing follow-ups, accepts vague hedges unchallenged, and the dialogue is punctuated by filler affirmations rather than sharp redirects.

“Right, right”

“Do you still see that action that the fda, other government groups are coming after pharmacies for those that are continuing to compound it”